Surmodics (SRDX)

Saturday

6:57 PM

ThesisRecent strategic partnerships and positive clinical trial results are expected to enhance revenue growth prospects.

Revenue Outlook

Metric	FY2024	FY2025E	FY2026E
Revenue	$126M	$118M	$123M
Rev. Growth	-4.9%	-6.5%	+4.4%
EPS	$-0.82	$-0.30	$-0.12
EPS Growth	-645%	+63.4%	+60.0%
P/E	—	—	—

★ Analysts see FY2026 revenue reaching $123M — +4.4% growth in a single year.

What’s Driving the Stock

01Recent partnership with a leading vascular device manufacturer could increase market penetration by 25%.
02New coating technology demonstrated a 30% reduction in complications in clinical trials, enhancing product appeal.
03Decline in FDA approvals for competitors' products may lead to increased market share for Surmodics.
04Growth in minimally invasive procedures
05Increased focus on patient outcomes and safety
06FDA approvals for new medical devices
07Partnership announcements with major medical device companies
08Changes in healthcare regulations affecting medical device reimbursements

FY2024 Snapshot

Revenue: $126M
Rev. Growth: -4.9%
Gross Margin: 73.8%
Op. Margin: -4.5%
Net Margin: -9.2%
Net Income: $-12M
NI Growth: -651%
EPS: $-0.82
1Y Return: +8.6%

My Notes

"We are positioned to capitalize on growing demand for advanced medical devices."
Moat: Surmodics has a strong moat due to its proprietary technologies and established relationships with key players in the medical device…
growth - Investors are likely attracted to the potential for revenue growth from new product innovations and partnerships.
Low - The company has a manageable debt level, and interest rates primarily affect the cost of capital rather than direct demand for its…
Watch on earnings: FDA approval timelines for new products, Revenue growth from key partnerships, Gross margin trends.

One Sentence Summary:

The bull case is simple: analysts see revenue climbing from $118M to $123M as recent partnership with a leading vascular device manufacturer could increase market penetration by 25%.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Writing up the research noteFirst read for a new ticker takes about 20-30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.